MGIM
BCRX icon

M&G Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

M&G Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-69,937
Closed -$979 – 512
2021
Q3 		$979 Buy
69,937
+10,754
+18% +$170K ﹤0.01% 635
2021
Q2 		$947 Buy
+59,183
New +$804K ﹤0.01% 627

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

M&G Investment Management's BCRX Position: Q4 2021 in Review

M&G Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2021, closing a stake of 69,937 shares — an estimated $979 sold.

M&G Investment Management first reported a position in BCRX in Q2 2021 and held it in 2 quarters. The position peaked at $979 in Q3 2021. 206 funds tracked by Wall St. Rank hold BCRX as of Q4 2021.

  • M&G Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • M&G Investment Management sold 69,937 BioCryst Pharmaceuticals shares in Q4 2021, an estimated $979.
  • M&G Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • M&G Investment Management's BioCryst Pharmaceuticals position peaked at $979 in Q3 2021.
  • 206 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2021.

Based on M&G Investment Management's 13F filing for Q4 2021, filed 18 Jan 2022.